Financials Bio-Works Technologies AB
Equities
BIOWKS
SE0007387089
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.94 SEK | 0.00% | +1.38% | -58.59% |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 190.3 | 176.7 | 243.9 | 276.8 | 959 | 736.4 |
Enterprise Value (EV) 1 | 101 | 122.7 | 167.5 | 243.7 | 856.3 | 670.6 |
P/E ratio | -8.07 x | -4.64 x | -5.76 x | -6.15 x | -66.3 x | -16.4 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 29.6 x | 26.9 x | 43.8 x | 38.3 x | 17 x | 17.8 x |
EV / Revenue | 15.7 x | 18.7 x | 30.1 x | 33.7 x | 15.2 x | 16.2 x |
EV / EBITDA | -4.6 x | -3.86 x | -4.01 x | -5.36 x | -81.8 x | -14.4 x |
EV / FCF | -7.04 x | -5.31 x | -6.58 x | -8.96 x | -104 x | -26.3 x |
FCF Yield | -14.2% | -18.8% | -15.2% | -11.2% | -0.96% | -3.81% |
Price to Book | 1.92 x | 2.87 x | 2.97 x | 7.39 x | 8.84 x | 10.9 x |
Nbr of stocks (in thousands) | 19,316 | 19,336 | 30,416 | 30,416 | 34,874 | 35,069 |
Reference price 2 | 9.850 | 9.140 | 8.020 | 9.100 | 27.50 | 21.00 |
Announcement Date | 18-04-24 | 19-04-26 | 21-04-28 | 21-04-28 | 22-04-27 | 23-04-28 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales 1 | 6.418 | 6.563 | 5.572 | 7.234 | 56.36 | 41.32 |
EBITDA 1 | -21.96 | -31.81 | -41.75 | -45.5 | -10.47 | -46.67 |
EBIT 1 | -23.58 | -33.51 | -42.13 | -45.65 | -10.96 | -47.14 |
Operating Margin | -367.42% | -510.56% | -756.07% | -631.1% | -19.44% | -114.09% |
Earnings before Tax (EBT) 1 | -23.66 | -37.96 | -42.11 | -45.02 | -9.37 | -44.7 |
Net income 1 | -23.66 | -37.96 | -42.11 | -45.02 | -12.94 | -44.95 |
Net margin | -368.6% | -578.32% | -755.8% | -622.33% | -22.96% | -108.79% |
EPS 2 | -1.220 | -1.970 | -1.392 | -1.480 | -0.4147 | -1.284 |
Free Cash Flow 1 | -14.34 | -23.09 | -25.46 | -27.21 | -8.227 | -25.53 |
FCF margin | -223.47% | -351.83% | -456.93% | -376.1% | -14.6% | -61.79% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 18-04-24 | 19-04-26 | 21-04-28 | 21-04-28 | 22-04-27 | 23-04-28 |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2020 S2 | 2021 S1 | 2022 S1 | 2022 S2 |
---|---|---|---|---|
Net sales 1 | 3.541 | 8.288 | - | 23.18 |
EBITDA 1 | - | 9.6 | - | -22.04 |
EBIT 1 | - | 9.256 | - | -22.31 |
Operating Margin | - | 111.68% | - | -96.25% |
Earnings before Tax (EBT) 1 | - | - | - | -21.36 |
Net income 1 | - | - | -23.53 | -21.49 |
Net margin | - | - | - | -92.75% |
EPS | -0.7900 | - | -0.6700 | - |
Dividend per Share | - | - | - | - |
Announcement Date | 21-02-19 | 21-08-20 | 22-08-19 | 23-02-17 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 89.2 | 54.1 | 76.4 | 33.1 | 103 | 65.9 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -14.3 | -23.1 | -25.5 | -27.2 | -8.23 | -25.5 |
ROE (net income / shareholders' equity) | -38.5% | -47.2% | -58.6% | -75.3% | -17.7% | -51% |
ROA (Net income/ Total Assets) | -22.1% | -24.3% | -33.9% | -42.7% | -8.23% | -27.7% |
Assets 1 | 107 | 156.5 | 124.3 | 105.3 | 157.2 | 162.1 |
Book Value Per Share 2 | 5.140 | 3.190 | 2.700 | 1.230 | 3.110 | 1.930 |
Cash Flow per Share 2 | 4.620 | 2.800 | 2.510 | 1.090 | 2.950 | 1.870 |
Capex 1 | 0.56 | 0.78 | 0.22 | 0.33 | 0.94 | 1.12 |
Capex / Sales | 8.66% | 11.9% | 3.95% | 4.51% | 1.67% | 2.72% |
Announcement Date | 18-04-24 | 19-04-26 | 21-04-28 | 21-04-28 | 22-04-27 | 23-04-28 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-58.59% | 10.45M | |
-2.54% | 187B | |
-1.85% | 106B | |
-4.26% | 66.9B | |
+1.39% | 49.45B | |
+16.82% | 48B | |
+4.06% | 40.84B | |
+3.49% | 26.48B | |
+0.65% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- BIOWKS Stock
- Financials Bio-Works Technologies AB